1
Return

Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDS

delete2026-06-12
delete0
PRE
AI
U
Uday Popat *
K
Konstantinos Lontos
R
Roland Bassett
J
Jitesh Kawedia
B
Ben C. Valdez
A
Alison M. Gulbis
A
Amin M. Alousi
G
Gheath Al-Atrash
Q
Qaiser Bashir
C
Chitra M. Hosing
J
Jin S. Im
P
Partow Kebriaei
I
Issa Khouri
D
David Marin
R
Rohtesh S. Mehta
Y
Yago Nieto
B
Betul Oran
A
Amanda Olson
M
Muzaffar H. Qazilbash
J
Jeremy Ramdial
DOI：10.1016/j.jtct.2026.06.014delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
• Phase two trial examining safety and efficacy of extended busulfan fractionation. • Recipients of longer busulfan fractionation had fewer severe toxicities. • Extending busulfan fractionation did not adversely affect relapse or NRM rates.

Journal

Transplantation and Cellular Therapy cover
Transplantation and Cellular Therapy
IF:
4.4
Papers:
2.1K
Citations:
4.4K

Organization

No organization information available
Cited Papers

Cited Papers

Citing Papers

Citing Papers